About US
Contact us
-
Sanofi shaves 207 R&D jobs in scaled-back reorgUnder assault from union leaders and government officials, Sanofi ($SNY) was forced to back off plans to engineer a major reorganization of its R&D operations in France. But it's going ahead with2013/7/4
-
Indian drugmakers balk at new Actos banIndian drugmakers are fighting the country's new ban on thediabetes drugpioglitazone, otherwise known asActos. Regulators suspended sales of the drug last week, citing safety worries, including concer2013/7/4
-
Is GlaxoSmithKline's China probe a harbinger of more?Are more drugmakers at risk of corruption probes inChina? After GlaxoSmithKline employees were detained in an investigation of "economic crimes," industry watchers point out that the Chinese governmen2013/7/3
-
FDA slaps a clinical hold on Achillion hep C drugShares of Achillion ($ACHN) skidded down 20% as the FDA put a clinical hold on itshepatitis Cdrug sovaprevir. Investigators had flagged a spike in liver enzymes--a classic sign of toxicity--among a gr2013/7/3
-
Chinese police corral GlaxoSmithKline employees in bribery probeChinese police rounded up GlaxoSmithKline employees in three cities as part of an investigation into "economic crimes," law enforcement there said in a statement. According to as-yet-unconfirmed repor2013/7/2
-
Private equity buyers eye offer for GlaxoSmithKline's drinks brandsPrivate equity firms Blackstone and Lion Capital are together eyeing an offer for GlaxoSmithKline's ($GSK) drinks brands Lucozade and Ribena. Up for sale as the U.K.-based drugmaker sheds lower-perfor2013/7/2
-
Merck KGaA sees U.S. as 'emerging market' for sales growthAnyone who follows the drug business knows that pharma companies big and not-so-much are aiming for growth in emerging markets. ButMerck KGaAhas a twist on that strategy: The German company sees the U2013/7/1
-
Pfizer, Bristol-Myers tout new VTE data on Eliquis, aiming for new useWhen is non-inferiority actually superior? When you're talking about new substitutes for the difficult-to-administerwarfarin. So, Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) happily announced today2013/7/1
-
Pfizer, Amgen eye $1B deal for Russian biosimilars developer BiocadRussianpharma dealmaking is heating up. On the heels of news thatPharmstandardis shopping its over-the-counter business, thebiosimilardeveloper Biocad is said to be entertaining offers from the likes2013/6/28
-
How to save money via adherence? Let us count the (possible) waysThat there's money to be saved on healthcare spending--and lots of it--is not in question. Exactly how to save that money through further generics use and better prescription adherence is what patient2013/6/28